Skip to content
PubMed This is a summary of 21 peer-reviewed journal articles Updated
Pulmonology · Mycobacterium avium complex pulmonary disease

What Do CT Scan Findings Mean in Pulmonary MAC Disease?

At a Glance

CT findings such as bronchiectasis, nodules, tree-in-bud changes, and cavities can support evaluation of pulmonary MAC, but they do not prove active infection. Doctors combine the scan with symptoms and repeated sputum or bronchial sample results before deciding whether treatment is needed.

The terminology on a chest CT (computed tomography) scan report can be confusing and alarming. Terms like bronchiectasis, nodules, tree-in-bud, and cavities describe specific patterns of structural change and inflammation in your lungs. While these findings help your care team understand the extent of your lung disease, they are only one piece of the puzzle. A CT scan alone cannot prove you have an active Mycobacterium avium complex (MAC) infection; it only shows patterns that must be interpreted alongside your physical symptoms and microbiological tests [1][2].

Here is what these common radiology terms mean in plain language and how they fit into your overall care.

Understanding Your CT Terms

Bronchiectasis

Bronchiectasis means that the airways (bronchi) in your lungs have become permanently widened, thickened, and damaged [3]. Healthy airways taper down as they go deeper into the lungs, much like the branches of a tree. In bronchiectasis, the airway walls are stretched, making it difficult for the lungs to clear out mucus. This condition has a bidirectional relationship with MAC: pre-existing bronchiectasis makes it easier for MAC to take hold, while an active MAC infection can cause further airway damage [4].

Nodules

Nodules are small, dense spots of tissue that show up as white dots on a CT scan. In the context of MAC, these can reflect localized areas of inflammation or infection. However, they are not specific to MAC; nodules can also be caused by other non-tuberculous mycobacteria (NTM), prior tuberculosis, fungal infections, or general inflammatory conditions [5].

Tree-in-Bud

The tree-in-bud pattern is a specific arrangement of nodules. It occurs when the smallest airways in the lung (bronchioles) become plugged with mucus and inflammation. On a CT scan, this looks like a branching tree with little buds sprouting from the ends [6][5]. While tree-in-bud often points to an airway infection, it is a nonspecific finding that can be seen in many different bacterial, mycobacterial, or inflammatory airway diseases [7][8].

Cavities and Consolidation

Cavities are gas-filled or air-filled spaces within the lung tissue. They can form when severe inflammation causes a section of lung tissue to break down [9][10]. While cavities are a concerning finding that often prompts evaluation for MAC, they can also be caused by tuberculosis, fungal infections, or other conditions. Consolidation is another term you might see, which refers to areas where the normally air-filled lung tissue has become solid with fluid or inflammation [9].

Two Common Patterns of MAC Disease

Doctors often group pulmonary MAC disease into two radiologic patterns. It is important to note that these are general trends, not strict rules, and patients can have overlapping features of both [11][12].

1. Nodular-Bronchiectatic Pattern
This form features bronchiectasis, nodules, and tree-in-bud signs, often located in the right middle lobe or the lingula (a part of the left lung) [11]. At a population level, this pattern is frequently seen in women without a history of smoking [13]. While it generally progresses more slowly than the fibrocavitary pattern, it can still cause significant lung damage over time and requires regular monitoring [14].

2. Fibrocavitary Pattern
The fibrocavitary pattern involves lung scarring (fibrosis) and the presence of cavities, typically in the upper lobes [12][15]. It is statistically more common in older men, individuals with a smoking history, or those with underlying lung diseases like COPD [13].

Features That May Indicate More Extensive Disease

Your care team will look at your CT scan for signs that the disease might be acting more aggressively. However, no single CT finding dictates your treatment plan.

  • The Presence of Cavities: Cavities are generally considered a higher-risk feature. Some observational studies show that cavitary MAC is associated with a higher risk of disease progression and lower treatment success rates compared to noncavitary disease [16][17]. Cavities that are large or are surrounded by consolidation are watched particularly closely [9].
  • Extensive Bronchiectasis: The more widespread the bronchiectasis, the harder it may be to clear the infection. Having bronchiectasis spread across multiple lobes of the lung is often linked to a higher burden of disease [18][19].

Diagnosis is Not the Same as Treatment

It is crucial to understand that officially diagnosing MAC lung disease is a separate step from deciding to treat it.

To formally diagnose MAC pulmonary disease, medical guidelines require three criteria to be met:

  1. Clinical Symptoms: such as chronic cough, fatigue, or weight loss.
  2. Radiology Findings: compatible CT findings like bronchiectasis, nodules, or cavities.
  3. Microbiology: at least two separate positive expectorated sputum cultures, or one positive culture from a bronchial wash/lavage (a procedure where fluid is collected directly from the lungs) [2][20].

Even if you meet all these criteria, it does not mean you must immediately start antibiotics. Sputum tests do more than just confirm the bacteria; they look at repeated positivity, the specific species, drug susceptibilities, and “smear status” (a rapid test showing the density of bacteria). Your care team will weigh these laboratory results, the severity of your symptoms, your CT scan, and your personal preferences to make an individualized decision [1].

For some patients with mild, noncavitary disease, doctors may recommend a “watch and wait” approach—which actually means active monitoring with serial sputum cultures and airway clearance therapies (exercises and devices to help cough up mucus) [14]. For others with cavitary or rapidly progressing disease, a multidrug antibiotic regimen may be necessary [21].

Safety Note: While a CT scan helps guide long-term management, seek prompt medical attention if you experience substantial coughing of blood, severe or rapidly worsening shortness of breath, chest pain, confusion, or low oxygen levels.

Common questions in this guide

What does bronchiectasis mean on a pulmonary MAC CT scan?
Bronchiectasis means the lung airways are permanently widened, thickened, and damaged, making mucus harder to clear. It can make it easier for MAC to persist, and MAC can further damage the airways. The extent of bronchiectasis helps clinicians judge the burden of lung disease.
What do nodules and a tree-in-bud pattern mean in MAC?
Nodules are small, dense spots that may reflect localized inflammation or infection. Tree-in-bud means the smallest airways are filled or inflamed in a branching pattern. Both findings can occur with MAC, but they can also result from other infections and inflammatory diseases, so neither finding is specific.
Does a CT scan confirm active pulmonary MAC infection?
No. CT patterns can support suspicion but cannot prove active MAC infection. Clinicians combine compatible symptoms, imaging, and microbiology; diagnosis generally requires at least two separate positive expectorated sputum cultures or one positive bronchial wash or lavage.
What is the difference between nodular-bronchiectatic and fibrocavitary MAC?
Nodular-bronchiectatic disease features bronchiectasis, nodules, and tree-in-bud changes, often in the right middle lobe or lingula, and often progresses more slowly. Fibrocavitary disease includes lung scarring and cavities, typically in the upper lobes, and can be more aggressive. A person may have overlapping patterns.
Are cavities on a MAC CT scan a serious finding?
Cavities are air-filled spaces formed when inflamed lung tissue breaks down. In pulmonary MAC, they are generally associated with a greater risk of progression and lower treatment success than noncavitary disease, especially when they are large or surrounded by consolidation. They warrant close clinical evaluation, but the scan alone does not determine treatment.
Do CT findings mean I need MAC antibiotics?
Not necessarily. Treatment decisions consider symptoms, repeated sputum culture results, the MAC species, drug susceptibility, smear status, CT findings, and your preferences. Mild noncavitary disease may be managed with active monitoring and airway clearance, while cavitary or rapidly progressing disease may require multidrug antibiotics.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Based on my CT scan, do I have a predominantly nodular-bronchiectatic or fibrocavitary pattern, or a mix of both?
  2. 2.Are there any cavities or areas of consolidation visible on my scan, and how do they compare to any previous scans I've had?
  3. 3.How extensive is the bronchiectasis, and does it seem to be causing my current symptoms?
  4. 4.Given my imaging, symptom history, and sputum culture results (including smear status and drug susceptibilities), do you recommend starting antibiotics or a "watch and wait" approach?
  5. 5.Can you refer me to a respiratory therapist or physical therapist to learn airway clearance techniques?
  6. 6.Could these CT findings be caused by something else, like a different infection, prior lung damage, or another condition?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (21)
  1. 1

    Mycobacterium avium Complex: Addressing Gaps in Diagnosis and Management.

    Daley CL, Winthrop KL

    The Journal of infectious diseases 2020; (222(Suppl 4)):S199-S211 doi:10.1093/infdis/jiaa354.

    PMID: 32814943
  2. 2

    Mycobacterium avium Complex Disease.

    Daley CL

    Microbiology spectrum 2017; (5(2)) doi:10.1128/microbiolspec.TNMI7-0045-2017.

    PMID: 28429679
  3. 3

    Diagnostic imaging in adult 
non-cystic fibrosis bronchiectasis.

    Juliusson G, Gudmundsson G

    Breathe (Sheffield, England) 2019; (15(3)):190-197 doi:10.1183/20734735.0009-2019.

    PMID: 31508157
  4. 4

    Radiological manifestations of allergic bronchopulmonary aspergillosis in adult asthmatic patients.

    Wahab F, Hussain Babar T, Nadeem SF, et al.

    Monaldi archives for chest disease = Archivio Monaldi per le malattie del torace 2026; doi:10.4081/monaldi.2026.3648.

    PMID: 42099257
  5. 5

    Lung infection with nontuberculous mycobacteria.

    Cano Rodríguez C, Castañer González E, Andreu Magarolas M, et al.

    Radiologia 2023; (65(5)):392-401 doi:10.1016/j.rxeng.2023.09.001.

    PMID: 37758330
  6. 6

    CT Imaging Characteristics of Nontuberculous Mycobacteria Lung Disease, Active Tuberculosis and Multi-Drug Resistant Tuberculosis.

    Xu L, Xu S

    Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG 2022; (39(2)):e2022008 doi:10.36141/svdld.v39i2.11829.

    PMID: 36118540
  7. 7

    Mycobacterium avium complex pulmonary disease in rheumatoid arthritis-associated interstitial lung disease under non-biologic immunomodulatory therapy: A case report.

    Tang R, Wang R, Han Y

    Medicine 2026; (105(21)):e48801 doi:10.1097/MD.0000000000048801.

    PMID: 42175403
  8. 8

    Comparison of chest CT findings in nontuberculous mycobacterial diseases vs. Mycobacterium tuberculosis lung disease in HIV-negative patients with cavities.

    Kim C, Park SH, Oh SY, et al.

    PloS one 2017; (12(3)):e0174240 doi:10.1371/journal.pone.0174240.

    PMID: 28346488
  9. 9

    Characteristic chest CT findings for progressive cavities in Mycobacterium avium complex pulmonary disease: a retrospective cohort study.

    Oshitani Y, Kitada S, Edahiro R, et al.

    Respiratory research 2020; (21(1)):10 doi:10.1186/s12931-020-1273-x.

    PMID: 31915013
  10. 10

    Natural course of the nodular bronchiectatic form of Mycobacterium Avium complex lung disease: Long-term radiologic change without treatment.

    Park TY, Chong S, Jung JW, et al.

    PloS one 2017; (12(10)):e0185774 doi:10.1371/journal.pone.0185774.

    PMID: 28968457
  11. 11

    Treatment of Mycobacterium avium Complex (MAC).

    Griffith DE

    Seminars in respiratory and critical care medicine 2018; (39(3)):351-361 doi:10.1055/s-0038-1660472.

    PMID: 30071550
  12. 12

    Outcomes of Mycobacterium avium complex lung disease based on clinical phenotype.

    Koh WJ, Moon SM, Kim SY, et al.

    The European respiratory journal 2017; (50(3)) doi:10.1183/13993003.02503-2016.

    PMID: 28954780
  13. 13

    Predictors of radiological aggravations of pulmonary MAC disease.

    Kodaka N, Nakano C, Oshio T, et al.

    PloS one 2020; (15(8)):e0237071 doi:10.1371/journal.pone.0237071.

    PMID: 32760104
  14. 14

    Long-term natural history of non-cavitary nodular bronchiectatic nontuberculous mycobacterial pulmonary disease.

    Moon SM, Jhun BW, Baek SY, et al.

    Respiratory medicine 2019; (151()):1-7 doi:10.1016/j.rmed.2019.03.014.

    PMID: 31047103
  15. 15

    Clinical characteristics of patients with bronchiectasis with nontuberculous mycobacterial disease in Mainland China: a single center cross-sectional study.

    Yin H, Gu X, Wang Y, et al.

    BMC infectious diseases 2021; (21(1)):1216 doi:10.1186/s12879-021-06917-8.

    PMID: 34872515
  16. 16

    Long-Term Treatment Outcome of Progressive Mycobacterium Avium Complex Pulmonary Disease.

    Fukushima K, Kitada S, Abe Y, et al.

    Journal of clinical medicine 2020; (9(5)) doi:10.3390/jcm9051315.

    PMID: 32370226
  17. 17

    Clinical Implications of Size of Cavities in Patients With Nontuberculous Mycobacterial Pulmonary Disease: A Single-Center Cohort Study.

    Kang HR, Hwang EJ, Kim SA, et al.

    Open forum infectious diseases 2021; (8(3)):ofab087 doi:10.1093/ofid/ofab087.

    PMID: 33796599
  18. 18

    Predicting progression of Mycobacterium avium complex pulmonary disease with treatment using explainable artificial intelligence techniques.

    Ozawa T, Asakura T, Chubachi S, et al.

    International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases 2026; (167()):108544 doi:10.1016/j.ijid.2026.108544.

    PMID: 41850623
  19. 19

    Developing a Simple Scoring System on CT Findings for Predicting Treatment Failure in Mycobacterium avium Complex Pulmonary Disease: The BCD (Bronchiectasis and Cavity Distribution) Score.

    Hayashi M, Takishima H, Cho H, et al.

    Open forum infectious diseases 2025; (12(9)):ofaf565 doi:10.1093/ofid/ofaf565.

    PMID: 41018706
  20. 20

    Nontuberculous mycobacterial pulmonary disease diagnosed by two methods: a prospective cohort study.

    Kim HJ, Lee JH, Yoon SH, et al.

    BMC infectious diseases 2019; (19(1)):468 doi:10.1186/s12879-019-4078-0.

    PMID: 31126235
  21. 21

    Treatment for Mycobacterium avium complex lung disease.

    Pan SW, Shu CC, Feng JY, Su WJ

    Journal of the Formosan Medical Association = Taiwan yi zhi 2020; (119 Suppl 1()):S67-S75 doi:10.1016/j.jfma.2020.05.006.

    PMID: 32446754

This page is for informational purposes only and does not constitute medical advice. A pulmonologist or infectious-disease clinician should interpret your CT together with your symptoms and culture results before making treatment decisions.

Get notified when new evidence is published on Mycobacterium avium complex disease.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.